The issuer is Lonza Finance International NV and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the bonds on the Luxembourg Stock Exchange (Regulated Market). The proceeds of the bonds will be used for refinancing and general corporate purposes.
Lonza’s issuer rating is currently BBB+ (S&P Global Ratings) with a stable outlook.
A consortium comprising of BNP Paribas, BofA, Citi, HSBC and JP Morgan were mandated to place the bond as Joint Active Bookrunners. Additionally, Goldman Sachs and ING were mandated as Joint Passive Bookrunners.
Key Data
Issue Size 10-Year Bond: EUR 500 million
Expected Payment Date: 25 May 2023
Maturity: 25 May 2033
Issue Price: 99.091 percent
Redemption Price: 100 percent
Coupon: 3.875 percent p.a.
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
Privacy Policy link
Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our business is structured to meet our customers‘ complex needs across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients. Our unparalleled breadth of offerings across divisions enables our customers to commercialize their discoveries and innovations in the healthcare industry.
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 17,500 full-time employees, we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 6.2 billion with a CORE EBITDA of CHF 2.0 billion in Full-Year 2022. Find out more at www.lonza.com
Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter
Lonza Group Ltd.
Münchensteinerstraße 38
CH4002 Basel
Telefon: +41 (61) 3168638
Telefax: +41 (61) 3169638
http://www.lonza.com
Telefon: +41 (79) 154-9522
E-Mail: lyle.wheeler@lonza.com
Head of Corporate Communications
Telefon: +41 (79) 599-6260
E-Mail: victoria.morgan@lonza.com
